Patents Assigned to Pfizer
  • Process and intermediates for growth hormone secretagogues
    Patent number: 6603002
    Abstract: This invention relates to a process for preparing compounds of the Formula I, wherein R1, R2 and Pt are as defined in the specification, which are intermediates in the synthesis of certain growth hormone secretagogue compounds. This invention further relates to processes for preparing the growth hormone secretagogues. The invention also relates to the compound of Formula I wherein R1 is H, R2 is 2,2,2-trifluoromethyl and Pt is Boc.
    Type: Grant
    Filed: July 31, 2002
    Date of Patent: August 5, 2003
    Assignee: Pfizer Inc.
    Inventors: Charles K. Chiu, David A. Griffith
  • Heterocyclic carboxamides
    Patent number: 6602874
    Abstract: A compound of the formula wherein X, Y, Z, R2 and R3 are as defined above, useful in treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated.
    Type: Grant
    Filed: May 22, 2001
    Date of Patent: August 5, 2003
    Assignee: Pfizer Inc.
    Inventor: Harry R. Howard
  • Sulfamoylheleroaryl pyrazole compounds as anti-inflammatory/analgesic agents
    Patent number: 6603008
    Abstract: This invention relates to a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein A and R1 are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R2 is NH2; R3 and R4 are each hydrogen, halo, (C1-C4)alkyl optionally substituted with halo and the like; and X1 to X4 are each hydrogen, halo, hydroxy, (C1-C4)alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: August 5, 2003
    Assignee: Pfizer Inc.
    Inventors: Kazuo Ando, Kiyoshi Kawamura
  • Canine coronavirus S gene and uses therefor
    Patent number: 6602504
    Abstract: The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene and encoded polypeptide for prophylaxis, diagnostic purposes and treatment of CCV infections.
    Type: Grant
    Filed: October 5, 2001
    Date of Patent: August 5, 2003
    Assignee: Pfizer Inc.
    Inventors: Timothy J. Miller, Sharon Klepfer, Albert Paul Reed, Elaine V. Jones
  • Sulfamoylheteroaryl pyrazole compounds as anti-inflammatory/analgesic agents
    Publication number: 20030144280
    Abstract: This invention relates to a compound of the formula: 1
    Type: Application
    Filed: December 31, 2002
    Publication date: July 31, 2003
    Applicant: PFIZER INC.
    Inventors: Kazuo Ando, Kiyoshi Kawamura
  • Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation
    Publication number: 20030143230
    Abstract: The invention relates to compositions and methods for treating or preventing inflammation, including rheumatoid arthritis (RA). The method comprises administering to mammals in need thereof an effective amount of a composition containing an agent that inhibits IL-1/18 combination with a TNF inhibitor.
    Type: Application
    Filed: November 27, 2002
    Publication date: July 31, 2003
    Applicant: Pfizer Inc.
    Inventors: Christopher A. Gabel, Mark A. Dombroski
  • Transgenic animals expressing human p25
    Publication number: 20030145343
    Abstract: The invention provides transgenic, non-human animals and transgenic non-human mammalian cells harboring a transgene encoding a p25 (activator of the protein kinase cdk 5) polypeptide.
    Type: Application
    Filed: February 11, 2003
    Publication date: July 31, 2003
    Applicant: Pfizer Inc.
    Inventors: John D. McNeish, Michael K. Ahlijanian
  • Method of selecting nonsedating H1-antagonists
    Publication number: 20030144336
    Abstract: A method is described in accordance with which one may select a nonsedating histamine H1-antagonist; comprising the step of determining whether a candidate H1-antagonist is a substrate for P-gp, especially P-gp expressed by MDR1 or mdr1a/1b, comprising the step of determining the brain-to-plasma AUC ratio in mdr1a/1b KO mice, and in WT mice, and selecting said candidate where the brain-to-plasma AUC ratio for said KO mice to the brain-to-plasma concentration ratio for said WT mice is 1.5 or greater.
    Type: Application
    Filed: May 30, 2002
    Publication date: July 31, 2003
    Applicant: Pfizer Inc.
    Inventors: Cuiping Chen, Jae S. Lee, John W. Watson
  • N-alkyl-adamantyl triazinyl benzamide derivatives
    Publication number: 20030144293
    Abstract: The present invention relates to novel to N-alkyl adamantyl triazinyl benzylamide derivatives of formmula I 1
    Type: Application
    Filed: November 12, 2002
    Publication date: July 31, 2003
    Applicant: Pfizer Inc.
    Inventor: Allen J. Duplantier
  • Processes for the preparation of substituted bicyclic derivatives for the treatment of abnormal cell growth
    Publication number: 20030144506
    Abstract: The invention relates to processes for preparing compounds of the formula 1 1
    Type: Application
    Filed: December 2, 2002
    Publication date: July 31, 2003
    Applicant: Pfizer Inc.
    Inventor: David Harold Brown
  • Polynucleotide molecules encoding neospora proteins
    Patent number: 6600027
    Abstract: The present invention provides isolated polynucleotide molecules comprising nucleotide sequences encoding GRA1, GRA2, SAG1, MIC1 and MAG1 proteins from Neospora caninum, as well as recombinant vectors, transformed host cells, and recombinantly-expressed proteins. The present invention further provides a polynucleotide molecule comprising the nucleotide sequence of the bidirectional GRA1IMAGI promoter of N. caninum. The present invention further provides genetic constructs based on the polynucleotide molecules of the present invention that are useful in preparing modified strains of Neospora cells for use in vaccines against neosporosis.
    Type: Grant
    Filed: March 25, 1999
    Date of Patent: July 29, 2003
    Assignees: Pfizer, Inc., Pfizer Products, Inc.
    Inventors: B. Rajendra Krishnan, Rebecca Madura, Christine Yoder, Becky Durtschi, David A. Brake
  • Arylsulfonyl hydroxamic acid derivatives
    Patent number: 6599890
    Abstract: A compound of the formula wherein R1, R2 R3, R4 R5, R6, R7, R8, R9 and Q are as defined above, useful in the treatment of a condition selected from the group consisting of arthritis, cancer, tissue ulceration, macular degeneration, restenosis, periodontal disease, epidermolysis bullosa, scleritis, and other diseases characterized by matrix metalloproteinase activity, AIDS, sepsis, septic shock and other diseases involving the production of TNF. In addition, the compounds of the present invention may be used in combination therapy with standard non-steroidal anti-inflammatory drugs (NSAID'S) and analgesics, and in combination with cytotoxic drugs such as adriamycin, daunomycin, cis-platinum, etoposide, taxol, taxotere and other alkaloids, such as vincristine, in the treatment of cancer.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: July 29, 2003
    Assignee: Pfizer Inc
    Inventors: Kim F. McClure, Mark C. Noe, Michael A. Letavic, Louis S. Chupak
  • Methods for preparing CETP inhibitors
    Patent number: 6600045
    Abstract: This invention relates to methods for preparing certain cholesteryl ester transfer protein (CETP) inhibitors and intermediates useful in the preparation of said CETP inhibitors.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: July 29, 2003
    Assignee: Pfizer Inc.
    Inventors: David B. Damon, Robert W. Dugger, Robert W. Scott
  • Quinoline derivatives useful for inhibiting farnesyl protein transferase
    Patent number: 6596735
    Abstract: The invention relates to compounds of the formula: and to pharmaceutically acceptable salts and solvates thereof wherein Y, R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings defined in the specification. The invention also relates to pharmaceutical compositions comprising said compounds and to the use of said compounds for inhibiting abnormal cell growth in mammals. The compounds of the above formula have activity as farnesyl protein transferase inhibitors.
    Type: Grant
    Filed: November 28, 2000
    Date of Patent: July 22, 2003
    Assignee: Pfizer Inc
    Inventor: Bingwei V. Yang
  • Biaryl ether derivatives useful as monoamine reuptake inhibitors
    Patent number: 6596741
    Abstract: The present invention relates to compounds of formula I: and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: July 22, 2003
    Assignee: Pfizer Inc
    Inventors: Harry R. Howard, Mavis D. Adam
  • Tartrate salt of a substituted dipeptide as growth hormone secretagogue
    Patent number: 6596867
    Abstract: This application relates to processes for making compounds of formula I, and processes for making intermediates useful in the processes for making compounds of formula I.
    Type: Grant
    Filed: December 11, 2000
    Date of Patent: July 22, 2003
    Assignee: Pfizer Inc.
    Inventors: Philip Albert Carpino, Paul Andrew Dasilva-Jardine, Bruce Allen Lefker, Jerry Anthony Murry
  • Fused bicyclic or tricyclic amino acids
    Patent number: 6596900
    Abstract: The compounds of the instant invention are bicyclic or tricyclic amino acids useful in the treatment of epilepsy, faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, pain, arthritis, neuropathological disorders, sleep disorders, visceral pain disorders, and gastrointestinal disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.
    Type: Grant
    Filed: April 16, 2002
    Date of Patent: July 22, 2003
    Assignee: Pfizer Inc
    Inventors: David Clive Blakemore, Justin Stephen Bryans, Sophie Caroline Williams
  • Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines
    Publication number: 20030133951
    Abstract: Pharmaceutical compositions are disclosed for the treatment of acute, chronic and/or neuropathic pain. The pharmaceutical compositions are comprised of a therapeutically effective combination of a nicotine receptor partial agonist and an analgesic agent and a pharmaceutically acceptable carrier. The analgesic agent is selected from opioid analgesics, NMDA antagonists, substance P antagonists, COX 1 and COX 2 inhibitors, tricyclic antidepressants (TCA), selective serotonin reuptake inhibitors (SSRI), capsaicin receptor agonists, anesthetic agents, benzodiazepines, skeletal muscle relaxants, migraine therapeutic agents, anti-convulsants, anti-hypertensives, anti-arrythmics, antihistamines, steroids, caffeine, and botulinum toxin. The method of using these compounds and a method of treating acute, chronic and/or neuropathic pain and migraine in a mammal including a human is also disclosed.
    Type: Application
    Filed: January 21, 2003
    Publication date: July 17, 2003
    Applicant: Pfizer Inc.
    Inventors: Jotham W. Coe, Steven B. Sands, Edmund P. Harrigan, Brian T. O'Neill, Eric J. Watsky
  • Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
    Publication number: 20030134844
    Abstract: This invention relates to the use of nicotinic acetylcholine receptor agonists for the treatment of restless legs syndrome (RLS). The invention further relates to the use of a nicotinic acetylcholine receptor agonist in the manufacture of a medicament for the treatment of RLS. The present invention also relates to a pharmaceutical composition for the treatment of RLS containing a nicotinic acetylcholine receptor agonist.
    Type: Application
    Filed: August 20, 2002
    Publication date: July 17, 2003
    Applicant: Pfizer Inc.
    Inventor: Mario D. Saltarelli
  • Hydrazinyl and nitrogen oxide pyrazoles
    Publication number: 20030134850
    Abstract: The present invention relates to hydrazinyl and nitrogen oxide pyrazoles of the formula I: 1
    Type: Application
    Filed: November 1, 2002
    Publication date: July 17, 2003
    Applicant: Pfizer Inc.
    Inventors: Subas M. Sakya, Bryson Rast